High Tech Pharm has been growing earnings at an average annual rate of 53.8%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been declining at an average rate of 1% per year. High Tech Pharm's return on equity is 8.8%, and it has net margins of 16.4%.
How High Tech Pharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A106190 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
70,183
11,475
3,122
817
30 Sep 25
75,600
11,980
3,743
0
30 Jun 25
74,653
10,564
3,691
0
31 Mar 25
73,578
12,627
3,835
0
31 Dec 24
77,513
13,710
3,790
0
30 Sep 24
81,558
14,558
3,281
0
30 Jun 24
83,502
13,522
3,120
0
31 Mar 24
82,545
11,596
2,714
0
31 Dec 23
76,772
8,076
2,601
0
30 Sep 23
79,175
8,114
1,993
0
30 Jun 23
94,102
7,931
2,315
0
31 Mar 23
102,150
6,799
2,568
0
31 Dec 22
102,947
5,873
2,705
0
30 Sep 22
88,688
5
3,337
0
30 Jun 22
70,212
-1,205
3,109
0
31 Mar 22
67,869
-2,977
3,317
0
31 Dec 21
73,287
-1,225
3,310
0
30 Sep 21
79,120
-1,054
4,515
0
30 Jun 21
85,343
-367
4,977
0
31 Mar 21
79,496
-2,535
4,727
0
31 Dec 20
74,462
-3,152
4,551
0
30 Sep 20
72,142
-5,630
3,182
0
30 Jun 20
73,147
-7,340
2,647
0
31 Mar 20
67,977
-4,743
2,397
0
31 Dec 19
63,068
-4,218
2,330
0
30 Sep 19
61,495
-917
2,595
0
30 Jun 19
54,381
1,116
2,569
0
31 Mar 19
60,013
2,413
2,592
-45
31 Dec 18
66,388
2,608
2,537
0
30 Sep 18
69,853
2,711
2,143
0
30 Jun 18
70,430
2,863
1,972
-16
31 Mar 18
67,593
2,640
1,928
1
31 Dec 17
66,050
2,100
2,029
101
30 Sep 17
65,534
4,866
2,261
120
30 Jun 17
58,847
3,514
2,303
136
31 Mar 17
54,081
4,449
2,103
164
31 Dec 16
54,836
5,280
1,991
19
30 Sep 16
50,660
3,024
1,815
60
30 Jun 16
53,373
5,400
1,664
55
31 Mar 16
53,452
6,263
1,724
66
31 Dec 15
48,092
6,544
1,664
80
30 Sep 15
47,604
8,613
1,807
45
30 Jun 15
45,844
9,079
1,946
50
Quality Earnings: A106190 has high quality earnings.
Growing Profit Margin: A106190's current net profit margins (16.4%) are lower than last year (17.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A106190 has become profitable over the past 5 years, growing earnings by 53.8% per year.
Accelerating Growth: A106190's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A106190 had negative earnings growth (-16.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.8%).
Return on Equity
High ROE: A106190's Return on Equity (8.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/22 13:57
End of Day Share Price
2026/05/22 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
High Tech Pharm Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.